BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34268923)

  • 21. Comparative evaluation of two-dimensional radiography and three dimensional computed tomography based dose-volume parameters for high-dose-rate intracavitary brachytherapy of cervical cancer: a prospective study.
    Madan R; Pathy S; Subramani V; Sharma S; Mohanti BK; Chander S; Thulkar S; Kumar L; Dadhwal V
    Asian Pac J Cancer Prev; 2014; 15(11):4717-21. PubMed ID: 24969909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcome and dosimetric parameters of chemo-radiation including MRI guided adaptive brachytherapy with tandem-ovoid applicators for cervical cancer patients: a single institution experience.
    Nomden CN; de Leeuw AA; Roesink JM; Tersteeg RJ; Moerland MA; Witteveen PO; Schreuder HW; van Dorst EB; Jürgenliemk-Schulz IM
    Radiother Oncol; 2013 Apr; 107(1):69-74. PubMed ID: 23639580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A dosimetric comparison of Volumetric Modulated Arc Therapy (VMAT) and High Dose Rate (HDR) brachytherapy in localized cervical cancer radiotherapy.
    Wali L; Helal A; Darwesh R; Attar M
    J Xray Sci Technol; 2019; 27(3):473-483. PubMed ID: 30958322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicentre treatment planning study of MRI-guided brachytherapy for cervical cancer: comparison between tandem-ovoid applicator users.
    Nomden CN; de Leeuw AA; Van Limbergen E; de Brabandere M; Nulens A; Nout RA; Laman M; Ketelaars M; Lutgens L; Reniers B; Jürgenliemk-Schulz IM
    Radiother Oncol; 2013 Apr; 107(1):82-7. PubMed ID: 23127774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CT based three dimensional dose-volume evaluations for high-dose rate intracavitary brachytherapy for cervical cancer.
    Murakami N; Kasamatsu T; Wakita A; Nakamura S; Okamoto H; Inaba K; Morota M; Ito Y; Sumi M; Itami J
    BMC Cancer; 2014 Jun; 14():447. PubMed ID: 24938757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dosimetric considerations when utilizing Venezia, Capri, Rotte double tandem, and tandem and ring with interstitial needles for the treatment of gynecological cancers with high dose rate brachytherapy.
    Schnell E; Thompson S; Ahmad S; Herman TS; De La Fuente Herman T
    Med Dosim; 2020 Spring; 45(1):21-27. PubMed ID: 31101569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rectal and bladder dose reduction with the addition of intravaginal balloons to vaginal packing in intracavitary brachytherapy for cervical cancer.
    Eng TY; Patel AJ; Ha CS
    Brachytherapy; 2016; 15(3):312-318. PubMed ID: 27032995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose rate in the highest irradiation area of the rectum correlates with late rectal complications in patients treated with high-dose-rate computed tomography-based image-guided brachytherapy for cervical cancer.
    Isohashi F; Akino Y; Matsumoto Y; Suzuki O; Seo Y; Tamari K; Sumida I; Sawada K; Ueda Y; Kobayashi E; Tomimatsu T; Nakanishi E; Nishi T; Kimura T; Ogawa K
    J Radiat Res; 2021 May; 62(3):494-501. PubMed ID: 33866361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dosimetric comparison of two different applicators and rectal retraction methods used in inverse optimization-based intracavitary brachytherapy for cervical cancer.
    Biltekin F; Gultekin M; Yilmaz MT; Yildiz F
    J Contemp Brachytherapy; 2020 Feb; 12(1):35-43. PubMed ID: 32190068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stability of Intracavitary Applicator Placement for HDR Brachytherapy of Cervix Cancer.
    Balsdon A; Timotin E; Hunter R; Diamond K
    J Med Imaging Radiat Sci; 2019 Sep; 50(3):441-448. PubMed ID: 31311722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-volume histogram analysis of composite EQD2 dose distributions using the central shielding technique in cervical cancer radiotherapy.
    Tamaki T; Noda SE; Ohno T; Kumazaki Y; Kato S; Nakano T
    Brachytherapy; 2016; 15(5):598-606. PubMed ID: 27475482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can MRI-only replace MRI-CT planning with a titanium tandem and ovoid applicator?
    Harkenrider MM; Patel R; Surucu M; Chinsky B; Mysz ML; Wood A; Ryan K; Shea SM; Small W; Roeske JC
    Brachytherapy; 2018; 17(5):747-752. PubMed ID: 29945764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamics of High Risk Clinical Target Volume reduction during Brachytherapy and impact on its coverage in patients with inoperable cervical cancer.
    Pobijakova M; Scepanovic D; Paluga M; Fekete M; Mardiak J
    Neoplasma; 2018 Mar; 65(3):425-430. PubMed ID: 29788726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose and volume parameters for MRI-based treatment planning in intracavitary brachytherapy for cervical cancer.
    Kirisits C; Pötter R; Lang S; Dimopoulos J; Wachter-Gerstner N; Georg D
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):901-11. PubMed ID: 15936576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reporting and validation of gynaecological Groupe Euopeen de Curietherapie European Society for Therapeutic Radiology and Oncology (ESTRO) brachytherapy recommendations for MR image-based dose volume parameters and clinical outcome with high dose-rate brachytherapy in cervical cancers: a single-institution initial experience.
    Mahantshetty U; Swamidas J; Khanna N; Engineer R; Merchant NH; Deshpande DD; Shrivastava S
    Int J Gynecol Cancer; 2011 Aug; 21(6):1110-6. PubMed ID: 21633296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaginal tolerance of CT based image-guided high-dose rate interstitial brachytherapy for gynecological malignancies.
    Murakami N; Kasamatsu T; Sumi M; Yoshimura R; Harada K; Kitaguchi M; Sekii S; Takahashi K; Yoshio K; Inaba K; Morota M; Ito Y; Itami J
    Radiat Oncol; 2014 Jan; 9():31. PubMed ID: 24456669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of 2D vs. 3D dosimetry for Rotte 'Y' applicator high dose rate brachytherapy for medically inoperable endometrial cancer.
    Beriwal S; Kim H; Heron DE; Selvaraj R
    Technol Cancer Res Treat; 2006 Oct; 5(5):521-7. PubMed ID: 16981795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. De-escalation of the cumulative central radiation dose according to the tumor response can reduce rectal toxicity without compromising the treatment outcome in patients with uterine cervical cancer.
    Kim KH; Kim S; Kim GE; Koom WS; Kim SW; Nam EJ; Suh CO; Kim YB
    Gynecol Oncol; 2015 Dec; 139(3):439-46. PubMed ID: 26456139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of dosimetric and clinical parameters on clinical side effects in cervix cancer patients treated with 3D pulse-dose-rate intracavitary brachytherapy.
    Levitchi M; Charra-Brunaud C; Quetin P; Haie-Meder C; Kerr C; Castelain B; Delannes M; Thomas L; Desandes E; Peiffert D
    Radiother Oncol; 2012 Jun; 103(3):314-21. PubMed ID: 22633813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deformable image registration-based contour propagation yields clinically acceptable plans for MRI-based cervical cancer brachytherapy planning.
    Chapman CH; Polan D; Vineberg K; Jolly S; Maturen KE; Brock KK; Prisciandaro JI
    Brachytherapy; 2018; 17(2):360-367. PubMed ID: 29331573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.